» Articles » PMID: 37318672

Mucin Glycans and Their Degradation by Gut Microbiota

Overview
Journal Glycoconj J
Publisher Springer
Date 2023 Jun 15
PMID 37318672
Authors
Affiliations
Soon will be listed here.
Abstract

The human intestinal tract is inhabited by a tremendous number of microorganisms, which are collectively termed "the gut microbiota". The intestinal epithelium is covered with a dense layer of mucus that prevents penetration of the gut microbiota into underlying tissues of the host. Recent studies have shown that the maturation and function of the mucus layer are strongly influenced by the gut microbiota, and alteration in the structure and function of the gut microbiota is implicated in several diseases. Because the intestinal mucus layer is at a crucial interface between microbes and their host, its breakdown leads to gut bacterial invasion that can eventually cause inflammation and infection. The mucus is composed of mucin, which is rich in glycans, and the various structures of the complex carbohydrates of mucins can select for distinct mucosa-associated bacteria that are able to bind mucin glycans, and sometimes degrade them as a nutrient source. Mucin glycans are diverse molecules, and thus mucin glycan degradation is a complex process that requires a broad range of glycan-degrading enzymes. Because of the increased recognition of the role of mucus-associated microbes in human health, how commensal bacteria degrade and use host mucin glycans has become of increased interest. This review provides an overview of the relationships between the mucin glycan of the host and gut commensal bacteria, with a focus on mucin degradation.

Citing Articles

The characteristics of intestinal microflora in infants with rotavirus enteritis, changes in microflora before and after treatment and their clinical values.

Yan Q, Chen Y, Gao E, Lu Y, Wu J, Qiu H Sci Rep. 2025; 15(1):4312.

PMID: 39910252 PMC: 11799311. DOI: 10.1038/s41598-025-88312-w.


The case for microbial intervention at weaning.

Flores J, Lubin J, Silverman M Gut Microbes. 2024; 16(1):2414798.

PMID: 39468827 PMC: 11540084. DOI: 10.1080/19490976.2024.2414798.


Metagenomic functional profiling: to sketch or not to sketch?.

Hera M, Liu S, Wei W, Rodriguez J, Ma C, Koslicki D Bioinformatics. 2024; 40(Suppl 2):ii165-ii173.

PMID: 39230701 PMC: 11373326. DOI: 10.1093/bioinformatics/btae397.


Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Nissle 1917 strain.

Falzone L, Lavoro A, Candido S, Salmeri M, Zanghi A, Libra M Gut Microbes. 2024; 16(1):2397874.

PMID: 39229962 PMC: 11376418. DOI: 10.1080/19490976.2024.2397874.


Modeling the effects of prebiotic interventions on luminal and mucosa-associated gut microbiota without and with challenge .

Wiese M, van der Wurff M, Ouwens A, van Leijden B, Verheij E, Heerikhuisen M Front Nutr. 2024; 11:1403007.

PMID: 39183984 PMC: 11342808. DOI: 10.3389/fnut.2024.1403007.


References
1.
Bansil R, Turner B . The biology of mucus: Composition, synthesis and organization. Adv Drug Deliv Rev. 2017; 124:3-15. DOI: 10.1016/j.addr.2017.09.023. View

2.
Ballester B, Milara J, Cortijo J . Mucins as a New Frontier in Pulmonary Fibrosis. J Clin Med. 2019; 8(9). PMC: 6780288. DOI: 10.3390/jcm8091447. View

3.
Johansson M, Hansson G . Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol. 2016; 16(10):639-49. PMC: 6435297. DOI: 10.1038/nri.2016.88. View

4.
Linden S, Sutton P, Karlsson N, Korolik V, McGuckin M . Mucins in the mucosal barrier to infection. Mucosal Immunol. 2008; 1(3):183-97. PMC: 7100821. DOI: 10.1038/mi.2008.5. View

5.
Alemao C, Budden K, Gomez H, Rehman S, Marshall J, Shukla S . Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders. Allergy. 2020; 76(3):714-734. DOI: 10.1111/all.14548. View